The Chicago trib ran an article about how pharma companies were not advancing new antibiotics due to a disagreement with the FDA on the clinical testing protocols. This jarred my memory that NVS bought Protez in 2008 to get access to PZ-601, supposedly at the time a very promising antibiotic. The 2008 press releases indicated that the clinical testing program would result in a regulatory filing in 2012. Since that time I have heard nothing about it. I do not see it listed in NVS' R&D summary.
Does anyone know whether this antibiotic was dropped, whether it is still in development or whether the clinical testing program has been put on the back burner while the clinical trial issues are ironed out with FDA?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.